Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 14/20 | 0.48 |
| ▸ | GSK3B | P49841 | 5/20 | 0.45 |
| ▸ | GSK3A | P49840 | 4/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5805693 | 0.82 | GSK3A (0.66) | PIN1GSK3BGSK3AAURKA | |
| SCHEMBL17168791 | 0.78 | PIN1 (0.53) | PIN1GSK3BGSK3A | |
| SCHEMBL31465483 | 0.78 | GSK3A (0.32) | GSK3BGSK3A | |
| SCHEMBL31465472 | 0.77 | IRAK4 (0.32) | PIN1GSK3BGSK3AAURKA | |
| SCHEMBL15221431 | 0.74 | PIN1 (0.47) | PIN1GSK3BGSK3A | |
| SCHEMBL15221514 | 0.72 | PIN1 (0.45) | PIN1GSK3BGSK3A | |
| SCHEMBL29777792 | 0.72 | PIN1 (0.47) | PIN1 | |
| SCHEMBL26921555 | 0.72 | PIN1 (0.47) | PIN1 | |
| SCHEMBL31465569 | 0.71 | SYK (0.47) | — | |
| SCHEMBL21492475 | 0.71 | PIN1 (0.44) | PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263753-A1 | BRIDGED CYCLE-BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND APPLICATION IN GENE EDITING | JUNO THERAPEUTICS INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250241912-A1 | USE OF BRIDGED CYCLE-BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE IN COMBINATION OF DNA POLYMERASE THETA INHIBITOR AND COMPOSITIONS AND APPLICATION IN GENE EDITING | JUNO THERAPEUTICS INC (US) | 2025-07-31 | — | — | US | disclosed |
| WO-2025049253-A1 | BRIDGED CYCLE‑BASED INHIBITORS OF DNA‑DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND APPLICATION IN GENE EDITING | JUNO THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263753-A1 | BRIDGED CYCLE-BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE AND COMPOSITIONS AND APPLICATION IN GENE EDITING | DTYMK, DCK, PHKG1 | PIN1 505/4885GSK3B 193/4885GSK3A 168/4885 |
| US-20250241912-A1 | USE OF BRIDGED CYCLE-BASED INHIBITORS OF DNA-DEPENDENT PROTEIN KINASE IN COMBINATION OF DNA POLYMERASE THETA INHIBITOR AND COMPOSITIONS AND APPLICATION IN GENE EDITING | POLQ, POLK, POLG | PIN1 543/4885GSK3B 204/4885GSK3A 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.